ABSK112 is a leading next-generation EGFR Exon20ins inhibitor with improved selectivity over wild-type EGFR and strong brain penetrating ability.

Source: https://www.prnewswire.com/news-releases/abbisko-presents-the-research-results-of-5-programs-at-the-2023-aacr-annual-meeting-301797704.html

ABSK112 is a leading next-generation EGFR Exon20ins inhibitor with improved selectivity over wild-type EGFR and strong brain penetrating ability.

Source: https://www.prnewswire.com/news-releases/abbisko-presents-the-research-results-of-5-programs-at-the-2023-aacr-annual-meeting-301797704.html

Checkpoint sees this as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer as olafertinib is a third-generation epidermal growth factor receptor or EGFR inhibitor.

Source: https://seekingalpha.com/article/4569044-checkpoint-therapeutics-updated-analysis?source=feed_all_articles

Checkpoint sees this as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer as olafertinib is a third-generation epidermal growth factor receptor or EGFR inhibitor.

Source: https://seekingalpha.com/article/4569044-checkpoint-therapeutics-updated-analysis?source=feed_all_articles

EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.

Source: https://www.prnewswire.com/news-releases/new-long-term-data-from-the-chrysalis-study-show-median-progression-free-survival-not-reached-after-33-6-months-of-follow-up-with-first-line-use-of-rybrevant-amivantamab-vmjw-and-lazertinib-combination-therapy-in-p

EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.

Source: https://www.prnewswire.com/news-releases/new-long-term-data-from-the-chrysalis-study-show-median-progression-free-survival-not-reached-after-33-6-months-of-follow-up-with-first-line-use-of-rybrevant-amivantamab-vmjw-and-lazertinib-combination-therapy-in-p

EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.

Source: https://www.prnewswire.com/news-releases/new-long-term-data-from-the-chrysalis-study-show-median-progression-free-survival-not-reached-after-33-6-months-of-follow-up-with-first-line-use-of-rybrevant-amivantamab-vmjw-and-lazertinib-combination-therapy-in-p

In the ongoing study, the original three cohorts included patients with non-small cell lung cancer, EGFR wild type, gastric and gastroesophageal junction adenocarcinoma and pancreatic hepatocellular and biliary tract cancers respectively.

Source: https://seekingalpha.com/article/4651686-affimed-n-v-afmd-q3-2023-earnings-call-transcript?source=feed_all_articles

The drug works by binding to the EGFR protein and blocking its activity, essentially locking out the receptor telling cancer cells to grow.

Source: https://www.ctvnews.ca/health/we-will-conquer-cancer-in-our-lifetime-cancer-patient-finds-hope-in-advanced-precision-medicine-1.6629934

They then tweaked this section so it binds to a human protein called EGFR, which is found on the outside of some cells, again using AlphaFold to work out the effects of the tweaks.

Source: https://www.newscientist.com/article/2366903-nanosyringes-could-inject-drugs-into-specific-cells-in-our-bodies/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=home